Radical Radiotherapy for Head and Neck Cancers in Ataxia Telangiectasia: A Comprehensive Evidence-Based Review for Radiation Oncologists

December 22, 2025

Radical Radiotherapy for Head and Neck Cancers in Ataxia Telangiectasia: A Comprehensive Evidence-Based Review for Radiation Oncologists

Essential Clinical Pearls for Radiation Oncologists

1. Extreme Radiosensitivity Requires Dramatic Dose Reduction
Patients with germline ataxia telangiectasia (A-T) exhibit 3-4 fold increased radiosensitivity compared to normal individuals. Conventional radiotherapy doses (60-70 Gy) are potentially fatal and absolutely contraindicated. Treatment requires 50-67% dose reduction from standard protocols, with careful reduction of dose per fraction (0.5-0.75 Gy per fraction) and intensive weekly monitoring.^[1]^[2]^[3]^[4]^[5]^[6]

2. Avoid Radiotherapy When Possible in Germline A-T
The preferred approach for confirmed germline A-T patients with cancer is to avoid radiotherapy entirely if alternative treatments exist. Prioritize surgical resection and carefully dose-reduced chemotherapy (also 50% dose reduction). When radiotherapy is unavoidable, it should generally be delivered with palliative rather than curative intent due to substantial toxicity risk.^[4]^[6]

3. Screen for Undiagnosed A-T Before Treatment
Maintain high clinical suspicion for A-T in patients presenting with progressive ataxia, oculocutaneous telangiectasia, elevated alpha-fetoprotein (>100 µg/L), immunodeficiency, multiple primary malignancies at young age, or history of severe radiation reactions. Genetic testing with ATM gene sequencing should be performed before initiating radiotherapy when A-T is suspected.^[3]^[6]^[7]^[8]

4. Somatic ATM Mutations Predict Exceptional Radiotherapy Response
Sporadic head and neck cancers harboring somatic ATM mutations (particularly truncating mutations) demonstrate exceptional responses to radiotherapy, with median local control of 4.62 years even with palliative treatment regimens. These patients can receive standard radiation doses and may achieve excellent outcomes. Tumor molecular profiling can identify these exceptional responder candidates.^[9]^[10]^[11]

5. Variant A-T Patients Still Require Treatment Modifications
Variant A-T with milder neurological symptoms, later onset, and residual ATM kinase activity (10-20% of normal) still confers significant radiosensitivity. Even patients who are ambulatory and have minimal systemic manifestations require dose modifications and close monitoring. Severe late toxicity can occur with standard doses, and radiation reactions may be the presenting feature leading to A-T diagnosis in adults.^[6]^[12]^[3]

6. HPV-Positive HNSCC Shows ATM Pathway Dysfunction
HPV-positive head and neck squamous cell carcinomas demonstrate enhanced radiosensitivity partly due to "lack of effectiveness in the ATM-orchestrated DNA damage response" despite expressing ATM protein. These tumors show limited additional radiosensitization with ATM inhibitors, suggesting that DDR inhibitor strategies should prioritize HPV-negative disease. This provides biological rationale for de-escalation trials in HPV-positive disease.^[13]^[14]^[15]^[16]

7. Individualized Dosing Using Biological Modeling
Successful ultra-low dose radiotherapy (21 Gy total using two-phase approach: 0.5 Gy × 26 fractions then 0.75 Gy × 20 fractions) has been achieved in pediatric A-T patients using tumor control probability modeling and weekly functional MRI monitoring for dose titration. Biological modeling with adjusted linear-quadratic parameters for A-T tissues can guide individualized treatment planning.^[4]

8. ATM/ATR Inhibitors Show Promise as Radiosensitizers
Clinical trials are evaluating ATM inhibitors (AZD0156, M3541) and ATR inhibitors (AZD6738/ceralasertib, M6620/berzosertib) combined with radiotherapy in HNSCC. These combinations enhance tumor control, activate the STING pathway and type I interferon response, increase CD8+ T-cell infiltration, and may work synergistically with immune checkpoint inhibitors. Phase I data shows tolerability and preliminary efficacy.^[16]^[17]^[18]^[19]^[20]^[13]

9. Heterozygous ATM Carriers Generally Tolerate Standard Radiotherapy
Approximately 0.5-1% of the population carries heterozygous ATM mutations and has 38% lifetime breast cancer risk. However, most heterozygotes tolerate standard radiotherapy without significantly increased acute or late toxicity. Recent studies show no special precautions are needed for routine radiotherapy in heterozygous carriers, though the rs1801516 SNP has been variably associated with modest increases in late fibrosis in some studies.^[21]^[22]^[23]^[3]

10. Multidisciplinary Coordination Is Essential
Management of A-T patients with cancer requires coordination among radiation oncologists, medical oncologists, clinical geneticists, hematologists (for immunodeficiency management), and specialists familiar with A-T. Extensive informed consent regarding severe toxicity risk, commitment to intensive monitoring protocols, and access to supportive care resources are critical components of safe treatment delivery.^[24]^[6]^[16]^[4]

Ataxia telangiectasia (A-T) presents unique and critical challenges for radiation oncologists treating head and neck malignancies. This rare autosomal recessive disorder, caused by biallelic mutations in the ATM gene, fundamentally alters cellular responses to ionizing radiation through impaired DNA double-strand break repair. The extreme radiosensitivity of A-T patients—demonstrated by 3-4 fold increased cellular sensitivity compared to normal tissues—makes conventional radiotherapy protocols potentially fatal, necessitating dramatically modified treatment approaches when radiation therapy cannot be avoided.^[1]^[2]^[3]^[4]

The intersection of A-T and head and neck cancers encompasses two distinct clinical scenarios requiring different management strategies. First, patients with germline A-T mutations who develop malignancies face severe treatment-related toxicity with standard therapies, requiring 50-67% dose reductions and meticulous monitoring. Second, and perhaps more encouraging for radiation oncologists, is the emerging recognition that sporadic head and neck cancers harboring somatic ATM mutations may represent exceptional responders to radiotherapy, with median local control periods exceeding 4.6 years even with palliative treatment regimens. Additionally, the therapeutic potential of combining ATM/ATR pathway inhibitors with radiotherapy in head and neck squamous cell carcinoma (HNSCC) represents a promising frontier, with multiple phase I/II clinical trials currently underway.^[5]^[6]^[7]^[8]^[9]^[4]^[10]^[11]^[12]^[1]

Understanding Ataxia Telangiectasia: Molecular Basis and Clinical Manifestations

Genetic and Molecular Pathophysiology

Ataxia telangiectasia results from mutations in the ATM (ataxia telangiectasia mutated) gene located on chromosome 11q22-23, encoding a serine/threonine protein kinase that serves as a master regulator of the DNA damage response. The ATM protein functions as a central coordinator of cellular responses to DNA double-strand breaks (DSBs), the most cytotoxic lesion induced by ionizing radiation. Upon detection of DSBs, ATM undergoes autophosphorylation and activates multiple downstream signaling cascades that orchestrate cell cycle checkpoints, DNA repair pathways, and apoptotic responses.^[13]^[14]^[15]^[7]^[16]

In normal cells, radiation-induced DSBs trigger ATM-mediated phosphorylation of histone H2AX (forming γH2AX), checkpoint kinase 2 (Chk2), p53, and numerous other substrates that collectively halt cell cycle progression and enable DNA repair. This coordinated response provides the therapeutic window for radiotherapy by allowing normal tissues to repair sublethal damage while cancer cells with compromised repair mechanisms undergo mitotic catastrophe. However, A-T patients lack functional ATM kinase activity, fundamentally disrupting this protective mechanism.^[14]^[15]^[2]^[3]^[17]^[13]

The radiosensitivity of A-T cells appears to result not from an inability to repair DSBs per se, but rather from a defect in recognizing and responding appropriately to radiation-induced damage. A-T cells fail to delay DNA synthesis following irradiation, continuing through the cell cycle without adequate time for repair. This "radioresistant DNA synthesis" phenotype leads to the accumulation of unrepaired chromosomal breaks, ultimately resulting in cell death at radiation doses that normal cells would tolerate.^[2]^[17]

Clinical Phenotype and Variant Forms

Classic A-T typically manifests in early childhood with progressive cerebellar ataxia becoming apparent when children begin walking, followed by oculocutaneous telangiectasia appearing around age 5-6 years. Additional features include oculomotor apraxia, dysarthric speech, immunodeficiency (particularly IgA and IgG deficiency), recurrent sinopulmonary infections, and characteristic laboratory findings including elevated serum alpha-fetoprotein (AFP) and increased chromosomal instability.^[1]^[16]^[3]^[11]

Critically for oncologists, variant A-T exists with residual ATM kinase activity, presenting with milder neurological symptoms, later onset, slower disease progression, and longer survival than classic A-T. Variant A-T patients may exhibit extrapyramidal features rather than prominent cerebellar ataxia, lack oculomotor apraxia, and demonstrate no significant immunodeficiency or pulmonary disease. These patients often remain ambulatory longer and may not receive a diagnosis until adulthood, particularly when a cancer diagnosis prompts genetic evaluation. The c.9023G>A (p.Arg3008His) variant, for example, retains residual kinase activity and associates with variant phenotypes. Despite milder systemic manifestations, variant A-T patients retain significant radiosensitivity and require treatment modifications, though they may tolerate slightly higher radiation doses than classic A-T patients.^[3]^[18]^[4]^[11]

Heterozygous ATM mutation carriers (approximately 0.5-1% of the population) generally exhibit normal clinical phenotypes but have increased breast cancer risk, with lifetime risk estimated at 38% for female carriers. Importantly for radiation oncology practice, heterozygous carriers appear to tolerate standard radiotherapy without significantly increased toxicity, though the rs1801516 single nucleotide polymorphism has been variably associated with increased late subcutaneous fibrosis in some but not all studies.^[19]^[20]^[11]^[21]^[3]

Cancer Susceptibility and Spectrum

Patients with A-T face a dramatically elevated lifetime cancer risk of 25-40%, representing a more than 100-fold increased risk compared to the general population. The cancer spectrum differs markedly between childhood and adulthood. During childhood, lymphomas and leukemias predominate, particularly T-cell acute lymphoblastic leukemia (T-ALL) and non-Hodgkin lymphomas, developing at a median age of 20-30 years—far younger than the general population. T-cell prolymphocytic leukemia (T-PLL) shows particularly strong association with A-T, with ATM mutations detected in up to 65% of T-PLL cases.^[6]^[1]^[7]^[8]^[16]^[11]^[22]

Adult A-T patients, particularly those with variant forms who survive longer, demonstrate increased susceptibility to solid tumors including breast, gastric, liver, thyroid, esophageal, and gynecological cancers. Multiple primary malignancies occur in 4-15% of A-T patients. Regarding head and neck cancers specifically, while nasopharyngeal lymphomas have been documented in pediatric A-T patients, cervical carcinoma has emerged as an association in adult patients and A-T heterozygote carriers. The first clinical report of cervical carcinosarcoma in a patient with confirmed A-T was published in 2021, highlighting the expanding recognition of the A-T cancer spectrum.^[1]^[7]^[23]^[24]^[10]^[11]^[25]^[6]

Radiotherapy in Germline Ataxia Telangiectasia: Extreme Radiosensitivity and Modified Protocols

Historical Context and Fatal Toxicity Reports

The extreme radiosensitivity of A-T patients was first recognized through devastating clinical outcomes when affected individuals received conventional radiotherapy. Multiple case reports from the 1960s-1980s documented unexpectedly severe, sometimes fatal reactions to standard radiation doses. These early experiences established that conventional radiotherapy dosing—typically 60-70 Gy for head and neck cancers—is absolutely contraindicated in A-T patients with severe phenotypes.^[1]^[16]^[2]^[3]^[4]

One of the seminal reports by Abadir and Hakami (1983) described a 9-year-old boy with A-T and nasopharyngeal undifferentiated lymphoma who demonstrated severe sensitivity to both radiation and chemotherapy yet was apparently cured with what would be considered inadequate therapy by conventional standards. This case highlighted that while A-T patients cannot tolerate standard treatment intensities, their malignancies may be exquisitely sensitive to even markedly reduced doses.^[10]^[1]

More recently, Byrd et al. (2012) reported a 44-year-old woman with variant A-T (mild neurological symptoms, ambulatory) who developed severe early and late radiation reactions following standard adjuvant radiotherapy (40 Gy in 15 fractions) for breast cancer. Despite having only mild neurological manifestations, her cellular radiosensitivity assays and ATM kinase activity (~12% of normal) predicted significant radiation sensitivity. She developed acute reactions "at the severe end of the normal spectrum" followed by progressive breast shrinkage and deformation—late toxicity manifestations that prompted the diagnosis of A-T. This case underscores that even variant A-T with residual ATM function requires treatment modification and that radiation reactions may be the presenting feature leading to A-T diagnosis in adults.^[3]

Radiobiological Considerations and Dose Calculation Models

The radiobiology of A-T tissues differs fundamentally from normal tissues in several key parameters. In vitro colony survival assays demonstrate that A-T cells exhibit approximately 3-4 fold increased radiosensitivity, with suggestions that the linear-quadratic model parameters differ substantially from normal cells. Based on in vitro data, A-T tissues may have an α (linear component) of approximately 1.0-1.6 and β (quadratic component) of 0 to 0.06, compared to pediatric glioma cells (α = 0.3 ± 0.2, β = 0.03 ± 0.018) and adult epithelial tumors (α = 0.3, β = 0.03).^[14]^[2]^[4]

DeWire et al. (2012) utilized these radiobiological parameters to design an individualized radiotherapy regimen for a 12-year-old girl with A-T and a malignant glioneuronal brain tumor. Using tumor control probability (TCP) modeling and assuming minimal repair between fractions in A-T cells, they calculated that approximately one-third of conventional doses might achieve therapeutic efficacy while limiting normal tissue toxicity. Their treatment was divided into two phases:^[4]

Phase I: 0.5 Gy per fraction for 26 fractions (13 Gy total), which yielded TCP of 99.1% based on modeling. After 10 fractions, functional MRI revealed a 2 mm increase in tumor size, prompting dose escalation.^[4]

Phase II: After reassessing α and β parameters based on in vivo response, they increased to 0.75 Gy per fraction for 20 additional fractions (15 Gy), bringing total dose to 21 Gy—dramatically lower than standard high-grade glioma treatment (60 Gy) yet predicted to achieve TCP of 99.7%.^[4]

This case demonstrated that even at these markedly reduced doses, grade 3 skin toxicity developed four weeks post-treatment (managed with topical agents), and the patient achieved six months of local control within the radiation field. Disease progression occurred outside the treatment field, consistent with the aggressive nature of high-grade gliomas, and the patient survived 14 months—a course consistent with malignant gliomas in non-A-T patients. Critically, this represented the first reported case using such an approach with minimal acute toxicity and demonstrable local tumor control, establishing proof-of-concept that modified radiotherapy is feasible in severe A-T.^[4]

General Dose Reduction Recommendations

Based on accumulated clinical experience across multiple case series, the general recommendation for radiotherapy in confirmed A-T patients is to reduce doses by 50-67% of standard protocols, with careful monitoring and potential for dose adjustment based on individual response. For chemotherapy, similar 50% dose reductions are commonly employed, with particular caution regarding alkylating agents, bleomycin, cyclophosphamide/ifosfamide, methotrexate, topoisomerase II inhibitors, and vinca alkaloids.^[4]^[26]^[10]^[11]

Several critical principles guide radiotherapy in A-T patients:

1. Avoid radiation when possible: For many A-T patients with cancer, the preferred approach is to avoid radiotherapy entirely if alternative treatments exist. Surgery and carefully dose-reduced chemotherapy should be prioritized.^[11]

2. Palliative intent: When radiotherapy is deemed necessary, it should generally be delivered with palliative rather than curative intent, given the substantial risk of severe toxicity.^[4]^[11]

3.Smaller fraction sizes: Smaller fraction sizes (e.g., 0.5-0.75 Gy per fraction rather than conventional 1.8-2.0 Gy) with fewer total fractions may be preferable, as this approach reduces the total dose while maintaining biological effectiveness in highly radiosensitive tissues.^[4]

4. Close monitoring: Weekly or even more frequent clinical assessments during radiotherapy are essential, with imaging studies (including functional imaging when available) to assess tumor response and guide potential dose adjustments.^[4]

5. Multidisciplinary approach: Management requires coordination among radiation oncologists, medical oncologists, clinical geneticists, and specialists familiar with A-T.^[7]^[27]^[11]

6. Individualization: Given the heterogeneity of A-T (classic versus variant forms, different specific mutations, varying residual ATM activity), treatment must be individualized rather than following rigid protocols.^[3]^[11]^[4]

Toxicity Profiles: Acute and Late Effects

Even with dramatically reduced doses, A-T patients experience significant treatment-related toxicity. Acute effects commonly include severe skin reactions, with erythema, hyperpigmentation, and potential progression to desquamation occurring at doses that would produce minimal reactions in normal individuals. Mucositis can be severe, even with reduced doses to mucosal surfaces.^[3]^[4]^[11]

The DeWire case demonstrated that alopecia within treatment portals, erythema, and hyperpigmentation developed during the low-dose treatment phases (13 Gy), with progression to grade 3 skin toxicity (requiring topical management with biafine and silvadene) occurring four weeks after completion of 21 Gy. This delayed acute toxicity (occurring 4 weeks post-treatment rather than during treatment) may represent unique kinetics in A-T patients.^[4]

Late effects remain incompletely characterized due to limited long-term survival in many A-T cancer patients, but documented complications include severe fibrosis, telangiectasia beyond baseline A-T-associated lesions, tissue necrosis, and secondary malignancies. The Byrd et al. breast cancer case demonstrated progressive breast deformation and shrinkage as late toxicity manifestations. Historical cases receiving conventional doses often experienced fatal toxicity or extremely debilitating late effects.^[1]^[16]^[2]^[28]^[3]

Importantly, even heterozygous ATM carriers may be at increased risk for certain late toxicities, though recent studies suggest that most heterozygotes tolerate standard radiotherapy well. A meta-analysis across breast and prostate cancer cohorts found that the rs1801516 variant was associated with odds ratios of 1.5 and 1.2 for upper quartile acute and late toxicity, respectively. However, a more recent study of breast cancer patients with ATM pathogenic variants found no significant increase in acute or late toxicity after adjuvant radiotherapy.^[19]^[20]^[21]

Somatic ATM Mutations in Head and Neck Cancer: Exceptional Responders to Radiotherapy

ATM as a Tumor Suppressor and Radiosensitization Biomarker

While germline ATM mutations cause devastating radiosensitivity, somatic ATM alterations in sporadic cancers may paradoxically predict exceptional responses to radiotherapy. This phenomenon reflects tumor-specific vulnerability: cancer cells with defective ATM-mediated DNA damage response cannot adequately repair radiation-induced DSBs, leading to preferential tumor cell death while surrounding normal tissues with intact ATM function can recover.^[5]^[15]^[8]^[29]

Ma et al. (2016) reported a landmark case of exceptional response to palliative radiotherapy that led to systematic investigation of this phenomenon. Patient A, a head and neck squamous cell carcinoma (HNSCC) patient treated with palliative "Quad Shot" radiotherapy (two fractions of 3.7 Gy per day for two days, repeated 3-4 times every 2-4 weeks), achieved prolonged local control with a small palliative radiation dose. Targeted sequencing revealed a frameshift mutation in the ATM gene at position 1455, along with 29 other somatic mutations. Notably, the tumor was p53 wild-type and also harbored a mutation in RAD50 and a frameshift mutation in MLH1.^[8]^[5]

To validate this observation, the investigators identified eight additional patients with truncating ATM mutations who received radiotherapy to gross disease. All eight demonstrated excellent responses, with median time to local recurrence of 4.62 years. Only two of the eight patients developed local recurrence within the radiation field. This local control duration far exceeds historical expectations for palliative treatment and rivals outcomes seen with curative-intent therapy.^[5]^[8]

Molecular Mechanisms of ATM Loss and Radiosensitivity

The enhanced radiosensitivity of ATM-deficient tumors operates through multiple interconnected mechanisms. ATM protein plays central roles in both non-homologous end joining (NHEJ) and homologous recombination (HR) DSB repair pathways. In NHEJ, ATM mediates recruitment of 53BP1-RIF1 and the shieldin complex to DSBs and directly phosphorylates 53BP1. Regarding HR, ATM controls DSB end resection through phosphorylation of multiple substrates and regulates the abundance of HR factors via CHK1-dependent transcription and promotion of HR protein stabilization.^[13]^[14]^[6]^[15]^[30]

ATM also phosphorylates DNA-PKcs at Thr-2609 in response to radiation, playing a fundamental role in NHEJ repair. Consequently, disrupting ATM function impairs both major DSB repair pathways, leading to accumulation of unrepaired breaks, increased chromosomal aberrations, and ultimately cell death.^[14]^[15]^[30]^[13]

Beyond direct repair functions, ATM activates cell cycle checkpoints that provide time for repair. ATM and CHK2 stabilize p53 by dissociating it from MDM2, activating downstream effectors such as p21 that induce G1 arrest. ATM also stabilizes p21-encoding mRNA by activating p38 MAPK. In S and G2 phases, ATM contributes to checkpoint activation that halts progression until repairs are completed. ATM-deficient cells lose these protective pauses, progressing through the cell cycle with unrepaired damage, culminating in mitotic catastrophe.^[15]^[13]^[14]

Genomic Context: ATM Mutations in HNSCC

Analysis of The Cancer Genome Atlas (TCGA) data revealed that mutations in 22 DNA repair genes occur in 15.9% of 9,064 tumors across 24 cancer types, with ATM mutations being the most prevalent. In HNSCC specifically, ATM alterations (including mutations and copy number losses) occur in approximately 5-13% of cases depending on the cohort and filtering criteria applied.^[5]^[7]^[31]

Lim et al. (2012) investigated ATM gene loss in HNSCC and found correlations with poor prognosis and treatment resistance in their cohort. Loss of distal chromosome 11q, which contains ATM, MRE11, and H2AX genes, has been associated with aggressive tumor behavior, radioresistance, and chromosomal instability in HNSCC. However, a subsequent study by Sankunny et al. demonstrated that HNSCC cell lines with distal 11q loss and resultant ATM deficiency showed compensatory upregulation of the ATR/CHK1 pathway and increased S and G2/M arrest after irradiation. ATR siRNA knockdown reversed the radioresistance phenotype in these ATM-deficient cell lines, suggesting that distal 11q loss may be a biomarker for both radioresistance and potential sensitivity to ATR/CHK1 pathway inhibitors.^[7]^[31]

The relationship between ATM status and HPV status in HNSCC adds additional complexity. HPV-positive HNSCC demonstrates enhanced radiosensitivity and superior clinical outcomes compared to HPV-negative disease. Some HPV-positive cell lines exhibit extremely low ATM expression, yet still show enhanced radiosensitivity. Detailed mechanistic studies revealed that HPV-positive HNSCC cells display a "lack of effectiveness in the ATM-orchestrated DNA damage response" that contributes to their DNA repair defect, even when ATM protein is expressed and retains kinase activity. This suggests that HPV infection disrupts ATM signaling pathway effectiveness through mechanisms beyond simple ATM loss.^[13]^[14]^[15]

Clinical Implications for Radiation Oncology Practice

The recognition that somatic ATM mutations predict exceptional radiotherapy responses has several important implications:

1. Biomarker identification: Routine molecular profiling of HNSCC (now increasingly common for targeted therapy selection) can identify ATM-mutant tumors. Patients with truncating ATM mutations may be candidates for de-escalated radiotherapy regimens or may achieve excellent outcomes even with palliative-intent treatments.^[5]^[8]^[29]

2. Treatment selection: For ATM-mutant tumors, radiation-based approaches may be particularly effective, potentially influencing decisions regarding surgery versus radiotherapy or the role of radiation in the oligometastatic setting.^[8]^[29]^[5]

3. Dose considerations: While germline ATM mutations require dose reduction, tumors with somatic ATM mutations may respond to standard or even reduced radiation doses, with surrounding normal tissues protected by their intact ATM function. The "Quad Shot" palliative regimen achieving 4.62-year median local control exemplifies this principle.^[29]^[5]^[8]

4. Molecular profiling of exceptional responders: When patients achieve unexpectedly durable responses to palliative or limited radiation, molecular profiling should be considered to identify ATM or other DNA repair gene alterations that may explain the response and inform future treatment decisions.^[5]^[8]

5. Combination strategies: ATM-deficient tumors may show increased sensitivity to DNA damage-inducing chemotherapies (cisplatin, carboplatin) concurrent with radiotherapy, as well as to PARP inhibitors and ATR inhibitors.^[6]^[32]^[29]^[5]

HPV Status, ATM Pathway, and Radiotherapy Response in Head and Neck Cancer

HPV-Positive HNSCC: Intrinsic Radiosensitivity and ATM Pathway Defects

Human papillomavirus (HPV)-positive head and neck squamous cell carcinomas, which now comprise the majority of oropharyngeal cancers in many regions, demonstrate markedly improved outcomes compared to HPV-negative disease. Five-year overall survival rates for HPV-positive oropharyngeal cancer approach 80-85% with standard chemoradiotherapy, compared to 40-50% for HPV-negative disease. This favorable prognosis stems partly from enhanced intrinsic radiosensitivity of HPV-positive tumors, a phenomenon clearly evident both clinically and in preclinical models.^[13]^[14]^[15]^[7]

Mechanistic investigations into this enhanced radiosensitivity have revealed complex interactions with the ATM-mediated DNA damage response pathway. Schieven et al. (2022) conducted a detailed study demonstrating that HPV-positive HNSCC cells display DNA repair kinetics and responses to ATM inhibition similar to ATM-deficient cells, despite expressing ATM protein. Key findings included:^[14]

DNA repair defects: Regardless of ATM expression levels, radiosensitive HPV-positive HNSCC cells displayed DSB repair kinetics similar to ATM-deficient cells. Upon ATM inhibition with KU55933, HPV-positive cell lines showed only marginal increases in residual radiation-induced γH2AX foci compared to the substantial increases seen in HPV-negative lines.^[14]

Cell cycle checkpoint alterations: ATM inhibition had minimal influence on G2 arrest at 24 hours post-irradiation in HPV-positive cell lines with low ATM expression, whereas HPV-negative lines showed pronounced checkpoint effects. This pattern resembles the checkpoint defects seen in classic ATM-deficient cells.^[14]

Reduced radiosensitization by ATM inhibition: When treated with ATM inhibitor plus radiation, HPV-positive HNSCC strains showed less radiosensitization (mean dose enhancement ratio 2.11 at 25% surviving fraction) compared to HPV-negative strains (3.24). After ATM inhibition, cell survival between the two groups became more similar.^[14]

Intact ATM kinase activity: Paradoxically, assessment of phosphorylation kinetics of ATM targets (KAP-1, CHK2) and ATM autophosphorylation after radiation did not indicate directly compromised ATM activity in HPV-positive cells. ATM inhibition delayed radiation-induced DNA end resection similarly in both HPV-positive and HPV-negative cells.^[14]

These findings led to the conclusion that HPV-positive HNSCC cells suffer from a "lack of effectiveness in the ATM-orchestrated DNA damage response" despite apparently functional ATM kinase. The molecular mechanisms underlying this ineffective ATM signaling remain under investigation but may involve HPV oncoproteins (E6, E7) disrupting downstream signaling or pathway integration.^[14]

Clinical Implications: De-escalation Strategies and ATM Pathway Targeting

The enhanced radiosensitivity of HPV-positive HNSCC has motivated numerous clinical trials investigating treatment de-escalation to reduce long-term toxicity while maintaining excellent cure rates. Understanding ATM pathway dysfunction in HPV-positive disease has several implications for these strategies:^[14]^[7]

1. Biological rationale for de-escalation: The ATM pathway defects provide mechanistic explanation for the observed radiosensitivity, supporting trials of reduced radiation doses (e.g., 60 Gy instead of 70 Gy) or reduced chemotherapy intensity in HPV-positive disease.^[14]

2. Limited utility of ATM inhibitors in HPV-positive HNSCC: Since HPV-positive tumors already exhibit ATM pathway dysfunction and show minimal additional radiosensitization with ATM inhibitors, these agents may be less beneficial in HPV-positive than HPV-negative disease. Clinical trial designs should stratify by HPV status when evaluating ATM/ATR inhibitors.^[7]^[14]

3. Alternative therapeutic targets: Given the reduced effectiveness of ATM pathway inhibition, other radiosensitization strategies (DNA-PK inhibitors, PARP inhibitors in selected cases, or immunotherapy combinations) may be more promising for HPV-positive HNSCC.^[30]^[33]

4. Biomarker development: ATM expression levels or functional assays of ATM pathway integrity might help identify HPV-positive tumors requiring standard-intensity treatment versus those suitable for de-escalation.^[14]

ATM and ATR Pathway Inhibitors Combined with Radiotherapy: Emerging Therapeutic Strategies

Rationale for DNA Damage Response Kinase Inhibition

The success of PARP inhibitors in BRCA-mutant cancers validated the concept of synthetic lethality—exploiting DNA repair deficiencies to selectively kill cancer cells. This principle extends to combining DNA damage response (DDR) kinase inhibitors with radiotherapy. By inhibiting key DDR kinases like ATM or ATR in combination with radiation (which induces DSBs and replication stress), a therapeutic window can potentially be created where cancer cells—which often have pre-existing DDR defects—cannot survive the combined assault, while normal tissues with intact backup pathways can recover.^[13]^[6]^[15]^[7]^[30]^[32]

The rationale is particularly strong in HNSCC for several reasons:

1. High frequency of DDR gene alterations: HNSCC exhibits frequent alterations in TP53 (50-80% of cases), leading to loss of G1 checkpoint function and increased dependence on ATR-mediated S and G2/M checkpoints.^[6]^[7]

2. Replication stress: HNSCC cells demonstrate high baseline replication stress due to oncogene activation, making them particularly dependent on ATR pathway for survival.^[7]^[6]

3. Radiation resistance mechanisms: Radioresistant HNSCC often exhibits upregulation of DDR pathways; inhibiting these may overcome resistance.^[15]^[30]^[13]

4. Potential for reduced radiotherapy doses: If DDR inhibitors effectively radiosensitize tumors, radiation doses might be reduced, potentially decreasing long-term toxicity while maintaining tumor control.^[34]^[7]

ATR Inhibitors: Leading Clinical Development

Ataxia telangiectasia and Rad3-related (ATR) kinase serves as the apical kinase activating S-phase and G2/M checkpoints in response to replication stress and single-strand DNA breaks. ATR tends to be overexpressed in HNSCC relative to adjacent normal tissues, representing a promising therapeutic target. Three ATR inhibitors have advanced to clinical testing: M6620 (VX-970/berzosertib), AZD6738 (ceralasertib), and BAY1895344 (elimusertib).^[6]^[7]

AZD6738 (ceralasertib): Foote et al. (2018) described the development of this potent and selective sulfoximine morpholinopyrimidine ATR inhibitor. AZD6738 demonstrates excellent preclinical pharmacokinetic characteristics suitable for once or twice daily dosing and achieves biologically effective exposure at moderate doses. Preclinical studies showed that AZD6738 radiosensitizes multiple cancer cell lines regardless of p53 and BRCA status. Importantly, combination with radiotherapy has not shown increased toxicity to normal tissues in preclinical studies, suggesting a favorable therapeutic index.^[7]^[35]^[6]

In HNSCC-specific preclinical models, AZD6738 demonstrated radiosensitizing effects in both HPV-positive and HPV-negative cell lines and xenograft models, with effects being independent of HPV status. One study showed greater radiosensitization with photon therapy in HPV-negative compared to HPV-positive cell lines, whereas dose enhancement ratios with proton therapy were similar between groups.^[7]

M6620 (berzosertib): This ATR inhibitor has been tested in combination with radiotherapy in several clinical trials. M6620 was shown to radiosensitize pancreatic cancer and lymphoma cell lines. A phase I study (NCT02589522) evaluated M6620 with whole brain radiation in patients with brain metastases from non-small cell lung cancer. Another trial (NCT02567422) investigated M6620 with concurrent chemoradiation (cisplatin) for head and neck squamous cell carcinoma.^[6]^[7]

Clinical trial results: Thomas et al. conducted a phase I study where M6620 combined with topotecan showed two partial responses and seven stable disease outcomes in 21 patients with advanced solid tumors, including a 60% response rate (partial response or prolonged stable disease) in platinum-refractory small cell lung cancer. Pharmacodynamic studies showed preliminary evidence of enhanced DNA double-strand breaks in response to combination treatment.^[6]

Karukonda et al. (2021) provided a comprehensive review of ATR inhibition in HNSCC treatment, emphasizing that targeting the ATR pathway may provide a favorable therapeutic index given that normal cells with an intact G1/S checkpoint should be preferentially spared relative to tumor cells with TP53 mutations. They noted that chromosomal alterations at 11q (distal 11q loss containing ATM, proximal 11q13 amplification containing cyclin D1) may predict sensitivity to ATR inhibitors in radioresistant HNSCC.^[7]

ATM Inhibitors: Preclinical Promise and Early Clinical Data

While ATM loss in tumors predicts radiosensitivity, pharmacologic ATM inhibition in tumors with intact ATM represents a strategy to enhance radiotherapy. Several ATM inhibitors are under investigation:^[13]^[15]^[30]^[34]^[12]

AZD0156: Jin et al. (2023) investigated this ATM inhibitor combined with radiotherapy in murine models of HNSCC (MOC2) and melanoma (B78). Key findings included:^[12]

· Combining RT and AZD0156 reduced tumor growth compared to either treatment alone^[12]

· Low-dose AZD0156 (1-100 nM) alone did not affect tumor cell proliferation but suppressed clonogenicity in combination with RT^[12]

· The combination synergistically induced STING-dependent type I interferon expression^[12]

· CD8+ T-cell migration and infiltration increased significantly with combination treatment^[12]

· Addition of anti-PD-L1 therapy improved antitumor response and lymphocyte activation^[12]

These findings demonstrate that ATM inhibition not only radiosensitizes tumors directly through impaired DNA repair but also enhances antitumor immunity via the STING pathway and type I interferon response. However, the combination also induced PD-L1 expression, suggesting that triple combination (ATM inhibitor + radiotherapy + anti-PD-L1) may be optimal.^[12]

M3541: Waqar et al. (2022) reported a phase I dose-escalation study evaluating this orally administered selective ATM inhibitor in combination with fractionated palliative RT in patients with solid tumors. Preclinical experiments showed that M3541 sensitizes tumor cell lines to radiation therapy in vitro and strongly enhances antitumor activity of ionizing radiation in vivo. The primary objectives were determining maximum tolerated dose and recommended phase II dose.^[34]

Toxicity considerations: A critical concern with ATM inhibitors is potential sensitization of normal tissues. However, Meidenbauer et al. (2024) found that inhibition of ATM or ATR in combination with hypo-fractionated radiotherapy leads to different immunophenotypes on transcript and protein levels in HNSCC. Cell death was induced mainly by combination therapy, stronger with ATR inhibition. The immune phenotype alterations were complex, with RT+ATR showing pro-inflammatory signaling (upregulation of ICOS-L, intensified secretion of IL-6 and IL-8) but also anti-inflammatory signals. RT+ATM demonstrated an immune-suppressive nature by RNAseq analysis.^[13]

DNA-PKcs Inhibitors and Combination Strategies

DNA-dependent protein kinase catalytic subunit (DNA-PKcs) plays crucial roles in non-homologous end joining and is another target for radiosensitization. Fabbrizi et al. (2024) investigated inhibition of ATM, ATR, and DNA-PKcs in six radioresistant HPV-negative HNSCC cell lines. Key findings:^[30]^[33]

· DNA-PKcs inhibition led to statistically significant accumulation of cells in G2/M phase^[30]

· Treatment with ATM inhibitor plus radiation showed no significant difference in G2/M accumulation compared to radiation alone^[30]

· ATR inhibitor combined with radiation caused reduction of cells in G2/M phase in some cell lines^[30]

These cell cycle effects have implications for therapeutic sequencing and suggest that DNA-PKcs inhibition may function through partially distinct mechanisms compared to ATM/ATR inhibition.^[30]

Immunomodulatory Effects: Integration with Checkpoint Blockade

An unexpected benefit of DDR inhibitor and radiotherapy combinations is enhancement of antitumor immunity. Radiation induces tumor cell death, releasing antigens and danger signals, activating dendritic cells, promoting antigen presentation, and facilitating T-cell priming. However, radiation also has immunosuppressive effects, including lymphocyte depletion and PD-L1 upregulation.^[7]^[9]^[12]

ATM/ATR inhibition may boost immunogenic effects of radiation through several mechanisms:

1. Enhanced STING pathway activation: Cytosolic DNA from unrepaired DSBs activates cGAS-STING signaling, triggering type I interferon production. ATM inhibition amplifies this response.^[12]

2. Increased CD8+ T-cell infiltration: Combination treatment enhances tumor-infiltrating lymphocytes, critical for durable antitumor immunity.^[12]

3. Major histocompatibility complex I upregulation: Improving antigen presentation to CD8+ T cells.^[12]

4. PD-L1 upregulation: While potentially immunosuppressive, this makes tumors more suitable targets for anti-PD-L1 therapy.^[7]^[12]

A phase I study combining AZD6738 with durvalumab (anti-PD-L1) showed one partial response in squamous cell carcinoma of the larynx and one potential complete response in NSCLC. This provides proof-of-concept for triple combination strategies integrating radiation, DDR inhibition, and immune checkpoint blockade.^[6]^[7]^[12]

Frontiers | Altering DNA Repair to Improve Radiation Therapy ...

Clinical Decision-Making: Practical Recommendations for Radiation Oncologists

Genetic Testing and Pre-treatment Assessment

Before initiating radiotherapy for head and neck cancers, radiation oncologists should maintain high clinical suspicion for undiagnosed A-T in specific scenarios:

1. Unexplained neurological symptoms: Progressive ataxia, oculomotor abnormalities, movement disorders, or peripheral neuropathy in cancer patients warrant evaluation.^[16]^[11]^[25]

2. History of severe radiation reactions: Patients who previously experienced severe acute or late toxicity from radiation, even at reduced doses, should be assessed for A-T or heterozygous ATM carrier status.^[3]^[21]

3. Multiple primary malignancies at young age: Particularly lymphomas/leukemias in childhood followed by solid tumors in young adulthood.^[11]^[25]

4. Elevated alpha-fetoprotein without hepatic explanation: AFP >100 µg/L in the absence of hepatocellular carcinoma suggests A-T.^[16]^[11]

5. Immunodeficiency: Recurrent infections, low IgA/IgG levels, especially combined with neurological findings.^[11]^[16]

6. Family history: Consanguinity, multiple relatives with early cancer, or known A-T in the family.^[11]

When A-T is suspected, genetic testing should include ATM gene sequencing for mutations, chromosomal breakage studies showing increased spontaneous and radiation-induced aberrations, and ATM protein expression/kinase activity assays. Testing can be performed on blood lymphocytes, lymphoblastoid cell lines, or fibroblasts.^[14]^[3]^[16]^[11]

For patients without germline A-T but with aggressive or treatment-refractory HNSCC, tumor molecular profiling including ATM mutational status may identify exceptional responder candidates or guide use of targeted therapies.^[5]^[8]^[29]

Treatment Decision Framework

For confirmed germline A-T patients with head and neck cancer:

Step 1 - Avoid radiotherapy if possible: Prioritize surgical resection and carefully dose-modified chemotherapy. Consultation with hematologist-oncologist experienced in A-T management is essential.^[11]^[27]

Step 2 - If radiotherapy unavoidable: Proceed only with palliative intent, extensive informed consent discussions regarding severe toxicity risk, multidisciplinary team involvement, and commitment to intensive monitoring.^[4]^[11]

Step 3 - Dose selection: Start with 50-67% of standard dose, using smaller fraction sizes (e.g., 0.5-0.75 Gy per fraction). Consider biological modeling if radiobiology expertise available.^[4]^[11]

Step 4 - Monitoring protocol: Weekly clinical examinations, mid-treatment imaging to assess response, dose adjustment based on tumor response and toxicity. Functional imaging (MRI with spectroscopy, perfusion, diffusion sequences) can provide early response indicators.^[4]

Step 5 - Supportive care: Aggressive prophylactic skin care, nutritional support, infection surveillance given immunodeficiency, psychological support.^[27]^[11]

For sporadic HNSCC with somatic ATM mutations:

These patients can typically receive standard radiotherapy protocols and may achieve exceptional responses even with reduced/palliative doses. Consider radiation-based treatment approaches as highly likely to be effective. Monitor for exceptional response and document outcomes to contribute to growing evidence base.^[5]^[8]

For HPV-positive HNSCC:

Standard protocols remain appropriate, though de-escalation trials are ongoing. ATM/ATR inhibitors may be less beneficial in HPV-positive than HPV-negative disease and should not be prioritized outside clinical trials. Focus immunotherapy combinations and other radiosensitization strategies in radioresistant cases.^[14]^[7]

For HPV-negative HNSCC:

Consider clinical trials evaluating ATM/ATR/DNA-PKcs inhibitors combined with radiotherapy, particularly for locally advanced, recurrent, or radioresistant disease. Tumor molecular profiling may identify subsets most likely to benefit (e.g., distal 11q loss for ATR inhibitors, ATM wild-type for ATM inhibitors).^[13]^[6]^[7]^[30]^[31]

Future Directions and Research Needs

Several critical questions remain unanswered and represent priorities for future investigation:

1. Predictive biomarkers: Developing clinically validated biomarkers beyond ATM mutational status to predict radiosensitivity and response to DDR inhibitors.^[5]^[14]^[7]^[18]

2. Optimal dosing and fractionation: Systematic studies determining optimal dose-fractionation schedules for A-T patients across different cancer types and A-T severity levels.^[4]^[26]

3. Long-term toxicity: Better characterization of late effects in A-T patients surviving beyond 2-5 years after radiotherapy.^[3]^[4]

4. Combination regimens: Phase II/III trials evaluating ATM/ATR inhibitors plus radiotherapy plus immunotherapy in HNSCC.^[6]^[7]^[12]

5. Heterozygote management: Clarifying whether ATM heterozygotes require treatment modifications and identifying which specific variants confer increased toxicity risk.^[19]^[20]^[21]

6. Variant A-T: Better defining the radiosensitivity spectrum in variant A-T with residual ATM activity to allow more individualized dosing.^[18]^[11]^[3]

Conclusion

Ataxia telangiectasia fundamentally challenges radiation oncology practice by presenting extreme radiosensitivity requiring dramatic treatment modifications while simultaneously illuminating pathways to enhance radiotherapy effectiveness in sporadic cancers. For the rare patient with germline A-T requiring radiotherapy for head and neck cancer, radiation oncologists must employ ultra-reduced doses (50-67% of standard), intensive monitoring, smaller fraction sizes and multidisciplinary coordination to balance tumor control against potentially fatal toxicity. The successful treatment of a pediatric brain tumor patient with only 21 Gy demonstrates feasibility of this approach.^[4]

Conversely, recognition that somatic ATM mutations predict exceptional radiotherapy responses opens opportunities for personalized treatment intensification or de-escalation based on tumor molecular profiles. The median 4.62-year local control achieved with palliative radiotherapy in ATM-mutant HNSCC exemplifies this principle. Additionally, the development of ATM and ATR inhibitors as radiosensitizers, particularly when integrated with immunotherapy, represents a promising therapeutic frontier with multiple ongoing clinical trials in HNSCC.^[13]^[5]^[6]^[7]^[8]^[12]

Understanding the ATM pathway's central role in radiation response enables radiation oncologists to optimize treatment for both the extreme vulnerability of germline A-T and the therapeutic opportunity presented by ATM-deficient tumors. As molecular profiling becomes routine in oncology practice, ATM status should be considered alongside other biomarkers when planning radiotherapy for head and neck cancers, ensuring both maximum efficacy and appropriate safety for each individual patient.

References :